Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2026-01-24 @ 4:17 AM
Study NCT ID:
NCT06026657
Status:
RECRUITING
Last Update Posted:
2025-07-08
First Post:
2023-08-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Sponsor:
Margaret Gatti-Mays
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
OSU-22237
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None